Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity

Journal of Neurosurgery

Volumn 98, Issue 3, 2003, Pages 591-598

  Hirose, Yuichi ^b   Kreklau, Emiko L ^b   Erickson, Leonard C ^b   Berger, Mitchel S ^b   Pieper, Russell O ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

DNA mismatch repair; DNA strand break; O6 methylguanine; O6 methylguanine DNA methyltransferase

Indexed keywords

6 O BENZYLGUANINE; DNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; DACARBAZINE; DRUG DERIVATIVE; GUANINE; O(6) BENZYLGUANINE; O(6)-BENZYLGUANINE;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CLONOGENESIS; CONTROLLED STUDY; DNA STRAND BREAKAGE; DRUG CYTOTOXICITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; MISMATCH REPAIR; MITOSIS INHIBITION; PHOSPHORYLATION; PRIORITY JOURNAL; CELL CULTURE; CELL SURVIVAL; CLONOGENIC ASSAY; DRUG EFFECT; GLIOMA; METABOLISM; MITOSIS; PATHOLOGY; TIME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL CYCLE PROTEINS; CELL SURVIVAL; COLONY-FORMING UNITS ASSAY; DACARBAZINE; G2 PHASE; GLIOMA; GUANINE; HUMANS; MITOSIS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0037365825     PISSN: 00223085     EISSN: None     Source Type: Journal    
DOI: 10.3171/jns.2003.98.3.0591     Document Type: Article

References (38)

1. Acharya S, Wilson T, Gradia S, et al: hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6. Proc Natl Acad Sci USA 93:13629-13634, 1996
2. Aquilina G, Crescenzi M, Bignami M: Mismatch repair, G2/M cell cycle arrest and lethality after DNA damage. Carcinogenesis 20:2317-2326, 1999
3. 6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br J Cancer 67:1299-1302, 1993
4. 6 -methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin. Clin Cancer Res 2:735-741, 1996
5. Bower M, Newlands ES, Bleehen NM, et al: Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 40:484-488, 1997
6. Brada M, Judson I, Beale P, et al: Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer 81:1022-1030, 1999
7. Bunz F, Dutriaux A, Lengauer C, et al: Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-1501, 1998
8. Chan TA, Hermeking H, Lengauer C, et al: 14-3-3σ is required to prevent mitotic catastrophe after DNA damage. Nature 401: 616-620, 1999
9. D'Atri S, Tentori L, Lacal PM, et al: Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol 54:334-341, 1998
10. Denny BJ, Wheelhouse RT, Stevens MFG, et al: NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 33:9045-9051, 1994
11. 4-methylthymine, or the cisplatin-d(GpG) adduct. Proc Natl Acad Sci USA 93:6443-6447, 1996
12. 6-benzylguanine for patients undergoing surgery for malignant glioma. J Clin Oncol 16:3570-3575, 1998
13. Glaab WE, Risinger JI, Umar A, et al: Characterization of distinct human endometrial carcinoma cell lines deficient in mismatch repair that originated from a single tumor. J Biol Chem 273: 26662-26669, 1998
14. Hawn MT, Umar A, Carethers JM, et al: Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. Cancer Res 55:3721-3725, 1995
15. Hickman MJ, Samson LD: Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents. Proc Natl Acad Sci USA 96:10764-10769, 1999
16. 2 checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. Cancer Res 61:5843-5849, 2001
17. 2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 61:1957-1963, 2001
18. Humbert O, Fiumicino S, Aquilina G, et al: Mismatch repair and differential sensitivity of mouse and human cells to methylating agents. Carcinogenesis 20:205-214, 1999
19. Ianzini F, Mackey MA: Spontaneous premature chromosome condensation and mitotic catastrophe following irradiation of HeLa S3 cells. Int J Radiat Biol 72:409-421, 1997
20. Kanamori M, Kon H, Nobukuni T, et al: Microsatellite instability and PTEN1 gene mutation in a subset of early onset gliomas carrying germline mutation or promoter methylation of the hMLH1 gene. Oncogene 19:1564-1571, 2000
21. 6-methylguanine residues in E. coli DNA. Nature 296:868-869, 1982
22. King RW, Jackson PK, Kirschner MW: Mitosis in transition. Cell 79:563-571, 1994
23. Klaude M, Eriksson S, Nygren J, et al: The comet assay: mechanisms and technical considerations. Mutat Res 363:89-96, 1996
24. Levati L, Marra G, Lettieri T, et al: Mutation of the mismatch repair gene hMSH2 and hMSH6 in a human T-cell leukemia line tolerant to methylating agents. Genes Chromosomes Cancer 23: 159-166, 1998
25. Lieung SY, Chan TL, Chung LP, et al: Microsatellite instability and mutation of DNA mismatch repair genes in gliomas. Am J Pathol 153:1181-1188, 1998
26. 6-benzylguanine combined with streptozotocin treatment enhances 1, 3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity. Cancer Res 54:4371-4375, 1994
27. Newlands ES, Blackledge GRP, Slack JA, et al: Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 65:287-291, 1992
28. Nurse P: Checkpoint pathways come of age. Cell 91:865-867, 1997
29. 2-phase DNA-damage checkpoint. Trends Cell Biol 10:296-303, 2000
30. Osoba D, Braba M. Yung WKA, et al: Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol 18:1481-1491, 2000
31. 6-alkylguanine by alkyltransferases. Mutat Res 462:83-100, 2000
32. 6-methylguanine-DNA methyltransferase expression. Pharmacol Ther 74: 285-297, 1997
33. 6-benzylguanine and hypoxia on the cytotoxicity of 1, 3-bis(2-chloroethyl)-1-nitrosourea in nitrosourea-resistant SF-763 cells. Cancer Chemother Pharmacol 32:477-481, 1993
34. 6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy. Clin Cancer Res 5:807-814, 1999
35. 6-methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics. Cancer Res 58:1068-1073, 1998
36. Singh NP, McCoy MT, Tice RR, et al: A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 175:184-191, 1988
37. 6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair. Cancer Res 59: 2402-2410, 1999
38. Yung WK, Prados MD, Yaya-Tur R, et al: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 12:2762-2771, 1999